

## APPENDIX 4D

### Consolidated Interim Financial Report for the half-year ended 31 December 2025

#### 1. Name of Entity

ClearVue Technologies Limited (ABN 45 071 397 487)

Reporting Period Half-year ended 31 December 2025

Previous Corresponding Reporting Period Half-year ended 31 December 2024

#### 2. Results for Announcement to Market

Financial results	Up / Down	% Change	2025	2024
Revenue from ordinary activities	NA	NA	-	-
Loss after tax from ordinary activities attributable to members	Down	9%	(5,246,848)	(5,723,823)
Loss attributable to members	Down	9%	(5,246,848)	(5,723,823)
Final and interim dividends	It is not proposed that either a final or interim dividend be paid.			
Record date for determining entitlements to the dividend	Not applicable			

#### 3. Net Tangible Asset Backing per Ordinary Share

Cents

Net tangible asset backing per ordinary share – current reporting period

0.77

Net tangible asset backing per ordinary share – previous reporting period

2.84

#### 4. Control Gained Over Entities

Details of entities over which control has been gained or lost

Not applicable

#### 5. Dividends Paid and Payable

Details of dividends or distribution payments

No dividends or distributions are payable.

#### 6. Dividend Reinvestment Plans

Details of dividend or distribution reinvestment plans

Not applicable

**7. Details of Associates**

---

Details of associates and joint venture entities	Not applicable
--	----------------

---

**8. Foreign Entities**

---

Foreign entities to disclose which accounting standards are used in compiling the report	Not applicable
--	----------------


---

**9. Review Opinion**

---

Details of any audit dispute or qualification
---

---



Theresa Smits  
Non-Executive Chair

Perth WA  
27 February 2026

For personal use only



ClearVue<sup>PV</sup>

**CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES**

ABN 45 071 397 487

Consolidated Interim Financial Report

For the half-year ended 31 December 2025

For personal use only

**COMPANY INFORMATION**

---

**DIRECTORS**

Ms Theresa Smit, Non- Executive Chairperson (appointed 8 July 2025, appointed as Chairperson 12 August 2025)  
Mr Michael Pixley, Non-Executive Director (appointed 8 July 2025)  
Mr Douglas Hunt, Managing Director (appointed 12 August 2025)  
Mr Liang Ji, Non-Executive Director (appointed 12 November 2025)  
Mr Victor Rosenberg, Non-Executive Chairperson, Non-Executive Director (resigned as Chairperson 12 August 2025, resigned as Director 28 November 2025)  
Mr Jamie Lyford, Executive Director (resigned 8 July 2025)  
Mr Gerd Hoenicke, Non-Executive Director (resigned 4 August 2025)  
Mr Charles Mowrey, Non-Executive Director (resigned 14 July 2025)

**COMPANY SECRETARY**

Mr Harry Miller  
Mr Brett Tucker

**REGISTERED OFFICE**

Suite 9 / 567 Newcastle Street  
West Perth  
WA 6005

**PRINCIPAL BANKERS**

National Australia Bank Limited  
Level 12, 100 St Georges Terrace  
Perth WA 6000

**AUDITORS**

Grant Thornton Audit Pty Ltd  
Level 43, Central Park  
152-158 St Georges Terrace  
Perth WA 6000

**SOLICITORS**

Steinepreis Paganin  
16 Milligan Street  
Perth WA 6000

**SHARE REGISTRY**

Automic Group  
Level 5, 191 St George Terrace  
Perth WA 6000

**STOCK EXCHANGE LISTING**

Shares are listed on the Australian Securities Exchange (ASX code: CPV)

**CONTENT**

---

	<u>PAGE</u>
<b>Directors' Report</b>	<b>1 – 3</b>
<b>Auditor's Independence Declaration</b>	<b>4</b>
<b>Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income</b>	<b>5</b>
<b>Condensed Consolidated Statement of Financial Position</b>	<b>6</b>
<b>Condensed Consolidated Statement of Changes in Equity</b>	<b>7</b>
<b>Condensed Consolidated Statement of Cash Flows</b>	<b>8</b>
<b>Notes to the Condensed Consolidated Financial Statements</b>	<b>9 – 17</b>
<b>Directors' Declaration</b>	<b>18</b>
<b>Independent Auditor's Report</b>	<b>19– 20</b>

For personal use only

**DIRECTORS' REPORT**

---

The Directors are pleased to present their Report together with the consolidated financial statements of ClearVue Technologies Limited ("the Company") and its Controlled Entities ("the Group") for the half-year ended 31 December 2025.

**1. DIRECTORS**

The name of the Directors in office at any time during or since the end of the half-year are:

Ms Theresa Smit, Non- Executive Chairperson (appointed 8 July 2025, appointed as Chairperson 12 August 2025)

Mr Michael Pixley, Non-Executive Director (appointed 8 July 2025)

Mr Douglas Hunt, Managing Director (appointed 12 August 2025)

Mr Liang Ji, Non-Executive Director (appointed 12 November 2025)

Mr Victor Rosenberg, Non-Executive Chairperson, Non-Executive Director (resigned as Chairperson 12 August 2025, resigned as Director 28 November 2025)

Mr Jamie Lyford, Executive Director (resigned 8 July 2025)

Mr Gerd Hoenicke, Non-Executive Director (resigned 4 August 2025)

Mr Charles Mowrey, Non-Executive Director (resigned 14 July 2025)

**2. PRINCIPAL ACTIVITIES**

The principal activities of the Company during the year were developing a sales and leads pipeline for the Company's products, licensing activities to appoint new manufacturers and distributors, as well as research and development activities applied to the Company's world leading solar glass and BIPV technology.

**3. REVIEW OF OPERATIONS AND FINANCIAL RESULTS**

The operating result of the Group for the current half-year is a loss of \$5,246,848 (2024: \$5,723,823).

**Operations**

**Forming a Strong Company Foundation**

During the first half of the fiscal year, the company leadership executed a consolidation and financial assessment phase. Major restructuring tasks were completed, and capital was repurposed to support commercialisation efforts. At the same time, essential product improvements continued to address barriers to BIPV adoption. Although reductions in operating costs resulting from the restructuring are not yet reflected due to contractual notice periods, these changes are expected to become evident in the next quarterly update.

**Investor Transparency and Engagement**

ClearVue recently launched its new Investor Hub to provide shareholders with centralized access to critical company data and direct communication with its leadership team. To mark the platform's debut, the company will host an inaugural investor webinar on 20 February 2026, to discuss its global commercialization strategy and mission to transform building materials into energy-generating surfaces.

**DIRECTORS' REPORT**

---

**Product Advancement and Certification**

ClearVue has advanced the rollout of its Gen3 technology, achieving energy outputs of over 60 Watts per square metre, which marks a 66% increase over previous iterations. This technological leap is accompanied by a 50% reduction in processing time for double-glazed units, significantly lowering production costs and facilitating more rapid scalability. Furthermore, the application of new spectrally selective coatings allows the solar glass to match the colour and reflectivity of standard Low-E glass, effectively removing previous aesthetic barriers for architectural integration. ClearVue has also completed IEC standard testing and factory inspections for its Thermal Bridge junction box design. The official certification will verify the product's compliance with international design and manufacturing standards.

**ClearVue Official License Partner Growth and Advancement**

ClearVue has hired two additional staff members to manage sustained high inquiry levels for new projects. These appointments precede the establishment of a Manila-based bid team intended to support the anticipated volume increase from licensing agreement launches with Viridian, Emirates Glass, Kukyoung, and Alutec. These launches are scheduled to occur over the coming months following the completion of partner training.

Official license partner, Concept Business Group, has commenced a project to re clad two 10-story commercial towers. This initiative serves as a global template for the retrofit market by demonstrating the conversion of aging assets into self-powering, green buildings.

The company is collaborating with Emirates Glass (UAE), Alutec (Qatar) and Kukyoung (South Korea) to address mandated Building-Integrated Photovoltaics (BIPV) markets. In these regions, government subsidies are actively reducing payback periods for developers.

**Addressing Energy Demand**

The Sightline Climate 2025 Investment Trends Report indicates that climate technology growth is increasingly driven by energy demand from AI infrastructure and data centres rather than emissions targets alone. As the industry prioritizes rapid power deployment to support significant data centre expansions, ClearVue's BIPV solutions facilitate on-site renewable energy generation. This local capacity addresses the need for immediate power while reducing the burden on overextended local grids.

**Board Strength and Industry Guidance**

The Board recently appointed Liang Ji as a Non-Executive Director, leveraging his technical expertise in photovoltaic standards from Underwriters Laboratories (UL) to provide valuable input throughout the TUV/UL certifications for the Gen3 Solar Vision Glass product line.

**DIRECTORS' REPORT**

---

**Material Business Risks**

Material business risks faced by the Company that are likely to have an effect on the financial prospects of the Company and how the company manage these risks include:

- Insufficient capital – given the reliance on capital, there is a risk of delays to projects, the research and development program and commercialisation strategy. There is also a going concern risk. This has been mitigated by way of operational reviews, cost cutting measures, capital raising activities and focus on investor relations.
- Higher than expected warrantee claims – although not a current significant risk, as the Company commercialises, high warrantee claims may result in unexpected cash outflows and lower gross margins. This is mitigated with back to back agreements with OEM suppliers and due diligence and a selection of reputable and high quality OEM's. As this risk becomes imminent, the Company has a quality management strategy ready to activate.
- Misappropriation of intellectual property – given intellectual property is the primary asset of the Company, any significant misappropriation of intellectual property may result in a loss competitive advantage, commoditisation of the product and litigation costs. This has been mitigated by way of an extensive patent portfolio, patent insurance and continuing innovation.
- Disruption to raw material supply – given the reliance on raw material supply from OEM's to enable the commercialisation of the Company and the continuing research and development program, this may result in project delays, higher input costs and missed milestones. This being mitigated by diversification of OEM's, secondary sourcing, forward purchasing and ongoing audits, reviews and relationship management with OEM's.

**Auditors Independence Declaration**

A copy of the Auditor's Independence Declaration as required under section 307C of the Corporations Act 2001 has been included on page 4.

Signed in accordance with a resolution of the Board of Directors.



Theresa Smits  
Non-executive Chair

Perth WA  
27 February 2026

---

**Grant Thornton Audit Pty Ltd**  
Level 43 Central Park  
152-158 St Georges Terrace  
Perth WA 6000  
PO Box 7757  
Cloisters Square  
Perth WA 6850  
T +61 8 9480 2000

## Auditor's Independence Declaration

### To the Members of ClearVue Technologies Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of ClearVue Technologies Limited for the half-year ended 31 December 2025. I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



J C Rubelli  
Partner – Audit & Assurance

Perth, 27 February 2026

---

grantthornton.com.au

ACN-130 913 594

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

**CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES**  
**ABN 45 071 397 487**

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER  
 COMPREHENSIVE INCOME**

**AS AT 31 DECEMBER 2025**

	<u>Note</u>	<u>Consolidated</u> <u>31 Dec 2025</u> \$	<u>Consolidated</u> <u>31 Dec 2024</u> \$
Revenue from contracts with customers		108,483	-
Other income	4	481,324	496,153
		<u>589,807</u>	<u>496,153</u>
Consulting expense		(1,699,958)	(1,495,660)
Depreciation and amortisation expense		(279,031)	(241,124)
Employee benefits expense		(1,589,932)	(1,588,180)
Finance costs		(42,188)	(31,972)
Legal fees		(265,861)	(133,673)
Material costs		(293,938)	(656,959)
Share-based payments	5	(38,020)	(346,833)
Travel expense		(334,884)	(418,659)
Other expenses	6	(1,292,843)	(1,306,916)
		<u>(5,836,655)</u>	<u>(6,219,976)</u>
<b>Loss before income tax</b>		(5,246,848)	(5,723,823)
Income tax expense		-	-
<b>Loss for the period</b>		<u>(5,246,848)</u>	<u>(5,723,823)</u>
<b>Other comprehensive income/loss</b>		-	-
<b>Total comprehensive loss for the period</b>		<u>(5,246,848)</u>	<u>(5,723,823)</u>
<b>Loss per share for loss attributable to the owners of the Company (cents)</b>			
Basic loss per share	12	(1.82)	(2.26)
Diluted loss per share	12	(1.82)	(2.26)

*See accompanying notes to the financial statements*

For personal use only

**CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES**  
**ABN 45 071 397 487**

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

**AS AT 31 DECEMBER 2025**

	<u>Note</u>	<b>Consolidated 31 Dec 2025 \$</b>	<b>Consolidated 30 Jun 2025 \$</b>
<b><u>ASSETS</u></b>			
<b>Current Assets</b>			
Cash and cash equivalents		2,047,160	3,591,254
Trade and other receivables	7	424,257	1,009,027
Other assets		483,896	711,476
<b>Total Current Assets</b>		2,955,313	5,311,757
<b>Non-Current Assets</b>			
Plant and equipment		460,254	525,210
Right-of-use asset		424,877	472,517
Intangible assets	8	6,249,614	6,052,189
Other assets		141,421	144,496
<b>Total Non-Current Assets</b>		7,276,166	7,194,412
<b>Total Assets</b>		10,231,479	12,506,169
<b><u>LIABILITIES</u></b>			
<b>Current Liabilities</b>			
Trade and other payables		1,005,474	2,011,957
Lease liabilities	9	84,727	80,664
Borrowings		-	409,158
Provisions		106,358	241,319
<b>Total Current Liabilities</b>		1,196,559	2,743,098
<b>Non-Current Liabilities</b>			
Lease liabilities	9	367,082	410,961
Provisions		71,956	101,875
<b>Total Non-Current Liabilities</b>		439,038	512,836
<b>Total Liabilities</b>		1,635,597	3,255,934
<b>Net Assets</b>		<b>8,595,882</b>	<b>9,250,235</b>
<b><u>EQUITY</u></b>			
Share capital	10	56,211,918	51,349,503
Share-based payments reserve	11	7,719,860	8,624,453
Accumulated losses		(55,335,896)	(50,723,721)
<b>Total Equity</b>		<b>8,595,882</b>	<b>9,250,235</b>

*See accompanying notes to the financial statements*

For personal use only

**CLEARVUE TECHNOLOGIES LIMITED AND ITS CONTROLLED ENTITIES**  
**ABN 45 071 397 487**

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**  
**FOR THE HALF-YEAR ENDED 31 DECEMBER 2024**

	Share Capital	Share-Based Payments Reserve	Accumulated Losses	Total
	\$	\$	\$	\$
<b>Balance at 1 July 2024</b>	<b>41,021,685</b>	<b>8,592,859</b>	<b>(39,545,637)</b>	<b>10,068,907</b>
Loss after income tax expense	-	-	<b>(5,723,823)</b>	<b>(5,723,823)</b>
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	-	(5,723,823)	(5,723,823)
Options exercised	3,055,500	(195,596)	195,596	3,055,500
Performance rights exercised	-	(134,863)	134,863	-
Shares based payments	8,028	-	-	8,028
Ordinary shares issued	7,500,000	-	-	7,500,000
Share issue costs	(636,490)	-	-	(636,490)
Options issued	-	338,805	-	338,805
Options lapsed	-	(76,166)	76,166	-
<b>Balance at 31 December 2024</b>	<b>50,948,723</b>	<b>8,525,039</b>	<b>(44,862,835)</b>	<b>14,610,927</b>
<b>Balance at 1 July 2025</b>	<b>51,349,503</b>	<b>8,624,453</b>	<b>(50,723,721)</b>	<b>9,250,235</b>
Loss after income tax expense	-	-	<b>(5,246,848)</b>	<b>(5,246,848)</b>
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	-	(5,246,848)	(5,246,848)
Options exercised	309,700	-	-	309,700
Performance rights issued	-	254,016	-	254,016
Performance rights lapsed	-	(480,000)	480,000	-
Shares based payments	307,940	-	-	307,940
Ordinary shares issued	4,624,115	-	-	4,624,115
Share issue costs	(379,340)	-	-	(379,340)
Options issued	-	305,476	-	305,476
Options lapsed	-	(984,085)	154,673	(829,412)
<b>Balance at 31 December 2025</b>	<b>56,211,918</b>	<b>7,719,860</b>	<b>(55,335,896)</b>	<b>8,595,882</b>

*See accompanying notes to the financial statements*

For personal use only

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 31 Dec 2024</b>
	\$	\$
<b>Cash flows from operating activities</b>		
Loss before income tax	(5,246,848)	(5,723,823)
<i>Adjustment for:</i>		
Exchange gain on foreign bank accounts	999	(1,009)
Depreciation of plant and equipment	84,762	64,092
Amortisation of intangible assets	194,269	177,101
Share-based payments	38,020	346,833
<b>Operating loss before working capital changes</b>	<b>(4,928,798)</b>	<b>(5,136,806)</b>
Changes in working capital:		
(Increase) in trade and other receivables	584,770	(428,115)
(Increase) in other assets	230,655	(240,047)
Increase in trade and other payables	(1,415,642)	269,664
Increase in provisions	(164,879)	45,504
<b>Net cash (used in) operating activities</b>	<b>(5,693,894)</b>	<b>(5,489,800)</b>
<b>Cash flows from investing activities</b>		
Patents and trademarks expenditure	(391,695)	(683,079)
Research and development expenditure	-	-
Purchase of plant & equipment	27,835	(56,546)
<b>Net cash (used in) investing activities</b>	<b>(363,860)</b>	<b>(739,625)</b>
<b>Cash flows from financing activities</b>		
Former Director loan repaid	-	-
Ordinary shares issued	4,624,115	7,500,000
Share issue costs	(379,340)	(636,490)
Options exercised	309,700	3,055,500
Lease payments	(39,816)	(38,437)
<b>Net cash from financing activities</b>	<b>4,514,659</b>	<b>9,880,573</b>
<b>Net increase in bank balances</b>	<b>(1,543,095)</b>	<b>3,651,148</b>
<b>Effect of currency translation on cash</b>	<b>(999)</b>	<b>1,009</b>
<b>Bank balances at beginning of half-year</b>	<b>3,591,254</b>	<b>3,554,485</b>
<b>Bank balances at end of half-year</b>	<b>2,047,160</b>	<b>7,206,642</b>

See accompanying notes to the financial statements

For personal use only

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE HALF-YEAR ENDED 31 DECEMBER 2025**

---

These notes form an integral part of and should be read in conjunction with the accompanying financial report:

**1. GENERAL INFORMATION**

*Nature of Operations*

The principal activities of the Group include research and development activities related to the Company's world leading solar glass technology and commercialisation activities for the same.

*Basis of Preparation and Statement of Compliance*

This general purpose consolidated interim financial statements has been prepared in accordance with the requirements of the Corporations Act 2001 and AASB 134 'Interim Financial Reporting'.

They do not include all of the information required in annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the Annual Report of the Group for the year ended 30 June 2025 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Securities Exchange Listing Rules and Corporations Act 2001.

*New Standards adopted at 1 July 2025*

There are no accounting pronouncements which have become effective from 1 July 2025 that have a significant effect on the Group's interim condensed consolidated financial statements.

The consolidated interim financial report has been approved and authorised for issue, in accordance with a resolution of Directors, on the 28 February 2025

The Group incurred an operating loss after income tax for the period ended 31 December 2025 of \$5,246,847 (\$5,723,823 loss for 2024) and reported net cash outflows from operating activities of \$5,693,894 (\$5,489,800 outflows for 2024) and investing activities of \$4,514,659 cash inflow (\$9,880,573 inflow for 2024). As at 31 December 2025, the Group had available cash and cash equivalents of \$2,047,160 (\$3,591,254 at 30 June 2025). The Company has the ability to defer or reduce its operating expenditure.

In assessing the appropriateness of the going concern assumption, the directors have considered the Group's successful history of capital raising, including the available At-Call Funding Facility and the ability to cut non committed expenditure.

This financial report has been prepared on a going concern basis which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE HALF-YEAR ENDED 31 DECEMBER 2025**

**2. ESTIMATES**

When preparing the Interim Financial Statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgements, estimates and assumptions applied in the Interim Financial Statements, including the key sources of estimation uncertainty, were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2025.

**3. SEGMENT INFORMATION**

Management has determined the operating segments based on reports reviewed by the Board of Directors for making strategic decisions. The current Board of Directors monitors the business based on operational and geographic factors and have determined that there is only one relevant business segment being ClearVue Technologies Limited. Whilst operations have commenced in the USA and the Netherlands, they are only nominal at this stage. The Group is domiciled in Australia and the vast majority of activity is in Australia.

**4. OTHER INCOME**

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 31 Dec 2024</b>
	\$	\$
Rebates and refunds	434,737	466,277
Other grants	36,600	-
Interest received	9,987	29,876
	<u>481,324</u>	<u>496,153</u>

**5. SHARE-BASED PAYMENTS EXPENSE**

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 31 Dec 2024</b>
	\$	\$
Shares issued to staff (ESOP)	-	338,805
Shares issued to consultants <sup>1</sup>	267,500	8,028
Shares issued to directors in lieu of fees <sup>2</sup>	40,440	-
Options issued to consultants <sup>3,4</sup>	305,476	-
Performance rights issued to directors (ESIP)	254,016	-
Options forfeited	(209,412)	-
Performance rights forfeited	(620,000)	-
	<u>38,020</u>	<u>346,833</u>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

5. SHARE-BASED PAYMENTS EXPENSE - Continued

<sup>1</sup>On 16 October 2025 a total of 1,231,090 fully paid ordinary shares were issued to a consultant with a deemed price of \$0.217

<sup>2</sup>On 29 December 2025 a total of 288,864 fully paid ordinary shares were issued to the chair in lieu of director fees at a deem price of \$.013 per share

<sup>2</sup>On 28 November 2025, 4,000,000 unlisted options were authorised to be issued to consultants at \$0.30 expiring 28 November 2028.

<sup>3</sup>On 28 November 2025, 989,550 unlisted options were authorised to be issued to consultants at \$0.27 expiring 28 November 2027.

6. OTHER EXPENSES

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 31 Dec 2024</b>
	\$	\$
Advertising and promotion	110,492	241,244
Courier fees	37,345	124,720
Insurance expense	104,686	117,880
Listing fees	145,341	115,016
Conferences and trade shows	9,566	285,818
Product testing	582,763	167,589
Office expenses	134,501	119,054
General expenses	168,149	135,595
	<u>1,292,843</u>	<u>1,306,916</u>

7. TRADE AND OTHER RECEIVABLES

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 30 June 2025</b>
Trade receivables	2,504	140,740
Research & development rebate receivable	421,753	868,287
	<u>424,257</u>	<u>1,009,027</u>

For personal use only

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

8. INTANGIBLE ASSETS

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 30 Jun 2025</b>
	\$	\$
Patents and trademarks	3,933,193	3,666,079
Development asset	2,316,421	2,386,110
	<u>6,249,614</u>	<u>6,052,189</u>
<i>Movements in patents and trademarks for the half-year</i>	<b>\$</b>	
<b>Cost:</b>		
Balance at 1 July 2025	5,546,497	
Additions	391,693	
Disposals	-	
Balance at 31 December 2025	<u>5,938,190</u>	
<b>Accumulated amortisation:</b>		
Balance at 1 July 2025	1,094,055	
Amortisation for the period	124,579	
Disposals	-	
Balance at 31 December 2025	<u>1,218,634</u>	
<b>Impaired:</b>	786,363	
<b>Carrying amount:</b>		
Balance at 31 December 2025	<u>3,933,193</u>	
<i>Movements in development asset for the half-year</i>		
<b>Cost:</b>		
Balance at 1 July 2025	2,787,573	
Additions	-	
Balance at 31 December 2025	<u>2,787,573</u>	
<b>Accumulated amortisation:</b>		
Balance at 1 July 2025	401,463	
Amortisation for the period	69,689	
Balance at 31 December 2025	<u>471,152</u>	
<b>Carrying amount:</b>		
Balance at 31 December 2025	<u>2,316,421</u>	

The directors do not consider there have been any indicators of impairment of patents and trademarks and development during the half year up to the date of this report.

For personal use only

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

9. LEASE LIABILITIES

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 30 Jun 2025</b>
	\$	\$
Current	84,727	80,664
Non-Current	367,082	410,961

The Group has leases for the offices. The lease liabilities are secured by the related underlying assets. Future minimum lease payments at 31 Dec 2025 were as follows:

	<b>Minimum Lease Payments</b>			<b>Total</b>
	<b>Within 1 Year</b>	<b>1-5 Years</b>	<b>After 5 Years</b>	
	\$	\$	\$	\$
Lease payments	105,956	402,561	-	508,517
Finance charges	(21,229)	(35,479)	-	(56,708)
Net present value	<u>84,727</u>	<u>367,082</u>	<u>-</u>	<u>451,809</u>

*Lease payments not recognised as a liability*

Certain variable lease payments are not permitted to be recognised as lease liabilities and are expensed as incurred. The expense relating to payments not included in the measurement of a lease liability is as follows:

	<b>Consolidated 31 Dec 2025</b>	<b>Consolidated 30 Jun 2025</b>
	\$	\$
Depreciation expense	47,640	94,503
Interest expense	12,187	33,135
Variable lease payments	31,204	51,462

For personal use only

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

10. SHARE CAPITAL

	<u>31 Dec 2025</u>	<u>30 Jun 2025</u>	<u>31 Dec 25</u>	<u>30 Jun 2025</u>
	NO. OF	NO. OF	\$	\$
	SHARES	SHARES		
<u>Share issued and fully paid</u>				
Balance at 1 July	268,625,167	242,658,474	51,349,503	41,021,685
Options exercised <sup>1</sup>	-	1,575,000	309,700	3,392,900
Performance rights exercised	-	500,000	-	-
Shares Issued <sup>2,3</sup>	35,689,625	23,437,500	4,624,115	7,500,000
Share issue costs			(379,340)	(653,360)
Share-based payment <sup>4,5</sup>	1,519,954	454,193	307,940	88,278
<b>Balance at 31 December</b>	<b><u>305,834,746</u></b>	<b><u>268,625,167</u></b>	<b><u>56,211,918</u></b>	<b><u>51,349,503</u></b>

<sup>1</sup>On 25 September 2025 a total of 2,000,000 fully paid ordinary shares exercised via the At The Market facility for a total of \$309,700.

<sup>2</sup>On 1 July 2025 a total of 10,000,000 fully paid ordinary shares were issued as collateral for the At The Market facility.

<sup>3</sup>On 22 October 2025 a total of 25,689,625 fully paid ordinary shares were issued as a placement at \$.016 per share.

<sup>4</sup>On 16 October 2025 a total of 1,231,090 fully paid ordinary shares were issued to a consultant with a deemed price of \$0.217

<sup>5</sup>On 29 December 2025 a total of 288,864 fully paid ordinary shares were issued to the chair in lieu of director fees at a deem price of \$.013 per share.

The share capital of the Company consists only of fully paid ordinary shares; the shares do not have a par value. All shares are equally eligible to receive dividends and the repayment of capital and represent one vote at the shareholders' meeting of the Company.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

11. SHARE-BASED PAYMENTS RESERVE

	<u>31 Dec 2025</u>	<u>30 Jun 2025</u>
	\$	\$
Share plan for Directors *	515,927	515,927
Performance rights for Directors	3,840,000	3,840,000
Options issued to Consultants	788,456	637,653
Options issued under CSIP	-	209,412
Options issued under ESIP	495,518	495,518
Performance rights issued under ESIP	589,016	1,435,000
Options issued to the Board	1,490,943	1,490,943
	<u>7,719,860</u>	<u>8,624,453</u>

\* The share plan arises on the grant of loan for a term of 10 years to Directors and related parties for the purchase of the Company's ordinary shares under the ClearVue Loan Funded Share Plan in 2017. Amounts are transferred out of the reserve and into share capital when the loans are settled.

	NO. OF OPTIONS	NO. OF PERFORMANCE RIGHTS	\$
<i>Movements in Share based payment reserve</i>			
Balance at 1 July 2025	19,752,262	14,500,000	8,624,453
Options lapsed <sup>1</sup>	(2,500,000)	-	(154,673)
Options forfeited <sup>2</sup>	(3,000,000)	-	(209,412)
Options issued <sup>3,4</sup>	4,989,550		305,476
Performance forfeited <sup>5</sup>	-	(2,000,000)	(620,000)
Performance rights lapsed <sup>6</sup>	-	(1,500,000)	(480,000)
Performance rights issued <sup>7</sup>	-	3,000,000	254,016
Balance at 31 December 2025.	19,241,812	14,000,000	7,719,860

<sup>1</sup>On 30 November 2025, 2,500,000 unlisted options exercisable at \$0.40 lapsed.

<sup>2</sup>On 6 July 2025, 3,000,000 unlisted options exercisable at \$0.2475 were forfeited.

<sup>3</sup>On 28 November 2025, 4,000,000 unlisted options were authorised to be issued to consultants at \$0.30 expiring 28 November 2028.

<sup>4</sup>On 28 November 2025, 989,550 unlisted options were authorised to be issued to consultants at \$0.27 expiring 28 November 2027.

<sup>5</sup>On 4 July 2025, 500,000 Class E performance rights, 500,000 Class F performance rights and 1,000,000 Class G performance rights were forfeited.

<sup>6</sup>On 30 November 2025 a total of 500,000 Class I performance rights and 1,000,000 Class J performance rights lapsed.

<sup>7</sup>On 29 December 2025 a total of 3,000,000 performance rights were issued to the non-executive directors,

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
 FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

12. LOSS PER SHARE

	<u>31 Dec 2025</u>	<u>31 Dec 2024</u>
	\$	\$
Loss after income tax attributable to owners of Company	(5,246,848)	(5,723,823)
	#	#
Weighted average number of shares	288,972,956	252,947,914
	Cents	Cents
Basic loss per share	(1.82)	(2.26)
Diluted loss per share	(1.82)	(2.26)

13. DIVIDENDS

No dividend has been declared or paid out in the half-year ended 31 December 2025 (2024: nil). The directors do not recommend the declaration of a dividend.

14. FINANCIAL ASSETS

All financial assets are classified and recognised under amortised cost. There is none classified as fair value through profit or loss, nor fair value through other comprehensive income.

	<u>Consolidated 31 Dec 2025</u>	<u>Consolidated 30 Jun 2025</u>
	\$	\$
<i>Financial Asset – Amortised Cost</i>		
Cash and cash equivalents	2,047,160	3,591,254
Trade and other receivables	424,753	1,009,027
	<u>2,471,913</u>	<u>4,600,281</u>

15. CONTINGENT ASSETS & LIABILITIES

There were no contingent assets or liabilities as at 31 December 2025 (2024: nil).

For personal use only

**16. EVENTS ARISING SINCE THE END OF THE REPORTING PERIOD**

No matter or circumstances, not otherwise dealt with in this report have arisen since the end of the financial year to the date of this report which has significantly affected, or may significantly affect, the operations of the Group, the results of those operations or state of affairs of the Group in subsequent financial years.

For personal use only

**DIRECTORS' DECLARATION**

---

In the opinion of the directors of ClearVue Technologies Limited:

- (a) the condensed consolidated financial statements and notes set out on pages 8 to 16 are in accordance with the Corporations Act 2001, including:
  - (i) complying with Accounting Standard AASB 134 Interim Financial Reporting; and
  - (ii) giving a true and fair view of its financial position as at 31 December 2025 and of its performance for the period 1 July 2025 to 31 December 2025; and
- (b) at the date of this declaration, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The declaration is made in accordance with a resolution of the Board of Directors required by section 303(5)(a) of the Corporations Act 2001.



Theresa Smits  
Non-executive Chairman

Perth WA  
27 February 2025

## Independent Auditor's Review Report

### To the Members of ClearVue Technologies Limited

#### Report on the half-year financial report

##### Conclusion

We have reviewed the accompanying half-year financial report of ClearVue Technologies Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2025, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, including material accounting policy information, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of ClearVue Technologies Limited does not comply with the *Corporations Act 2001* including:

- a giving a true and fair view of the ClearVue Technologies Limited's financial position as at 31 December 2025 and of its performance for the half year ended on that date; and
- b complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

##### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

### Directors' responsibility for the half-year financial report

The Directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's responsibility for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD  
Chartered Accountants



J C Rubelli  
Partner – Audit & Assurance  
Perth, 27 February 2026